"medical and surgical retina"

During the past decade, Retina Associates of Utah conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 13 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 11 clinical trials were completed. i.e. 91.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Associates of Utah" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Jaeb Center for Health Research" with 3 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "ThromboGenics" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Associates of Utah" #1 collaborator was "National Eye Institute (NEI)" with 3 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Retina Associates of Utah" are "Diabetic Macular Edema" (7 trials), "Geographic Atrophy" (5 trials), "Macular Degeneration" (4 trials), "Macular Edema" (2 trials) and "Neovascular Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Retina Associates of Utah" in a lesser frequency.

Most popular intervention types in "Retina Associates of Utah" are "Drug" (25 trials), "Procedure" (6 trials), "Other" (5 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Faricimab" (9 trials), "Ranibizumab" (5 trials), "Aflibercept" (4 trials) and "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associates of Utah" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associates of Utah". undefined are not yet recruiting, 3 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Retina Associates of Utah, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associates of Utah, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".